Search - tctmd.com

Displaying 41 - 59 of 59

Sort: Relevancy | Date

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Presenter: Nick Curzen

September 15, 2014

Presentation TCT 2014

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux

September 15, 2014

Presentation TCT 2014

Cangrelor II: New Data from the FDA Advisory Board Panel

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Robert A. Harrington

September 15, 2014

Presentation TCT 2014

Cangrelor I: Data Essentials from the Champion Trials

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Deepak L. Bhatt

September 15, 2014

Presentation TCT 2014

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

Presenter: Dimitrios Alexopoulos

September 14, 2014

Presentation

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

Presenter: Philippe Généreux

April 02, 2014

Presentation ACC 2014

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Presenter: Philippe Généreux

March 30, 2014

Presentation TCT 2013

I'm Sure: Cangrelor Is Required In Addition!

Presenter: Gregg Stone

October 31, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Cangrelor Properties: PK, PD and More

Presenter: Sergio Leonardi

October 31, 2013

Presentation TCT 2013

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

Presenter: Deepak Bhatt

October 30, 2013

Presentation TCT 2012

Cangrelor: CHAMPION PHOENIX Update

Presenter: Harvey White

October 24, 2012

Presentation

Reduced Immediate Ischemic Events with Cangrelor in PCI: Pooled Analysis of the CHAMPION Trials Using the Universal Definition of MI

Presenter: 35236|Harvey White

March 16, 2012

Presentation

Menores Episodios Isquémicos Inmediatos con el Cangrelor en las PCI: Análisis Conjunto de los Ensayos Champion usando la Definición Universal de IM

Presenter: Harvey D. White

March 16, 2012

Presentation

Puenteando la Terapia Antiplaquetaria con Cangrelor en Pacientes que se someten a Cirugía Cardíaca

Presenter: Dominick J. Angiolillo

January 16, 2012

Presentation

Bridging Antiplatelet Therapy with Cangrelor in Patients Undergoing Cardiac Surgery

Presenter: Dominick J. Angiolillo

January 16, 2012

Advertisement

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Definitely To Prevent Stent Thrombosis and MI!

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: New Data from the FDA Advisory Board Panel

Cangrelor I: Data Essentials from the Champion Trials

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

I'm Sure: Cangrelor Is Required In Addition!

Cangrelor Will Be the Answer for Most in the Acute Setting!

Cangrelor Properties: PK, PD and More

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

Cangrelor: CHAMPION PHOENIX Update

Reduced Immediate Ischemic Events with Cangrelor in PCI: Pooled Analysis of the CHAMPION Trials Using the Universal Definition of MI

Menores Episodios Isquémicos Inmediatos con el Cangrelor en las PCI: Análisis Conjunto de los Ensayos Champion usando la Definición Universal de IM

Puenteando la Terapia Antiplaquetaria con Cangrelor en Pacientes que se someten a Cirugía Cardíaca

Bridging Antiplatelet Therapy with Cangrelor in Patients Undergoing Cardiac Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content